Brachytherapy Market By Technique (High Dose Rate (HDR) Brachytherapy, Low Dose Rate (LDR) Brachytherapy, Pulse Dose Rate (PDR) Brachytherapy, and Image Guided Brachytherapy (IGBT)), By Application (Prostate Cancer, Breast Cancer, Gynecological Cancer, Cervical Cancer, Skin Cancer, and Others), and By Region - Trends, Analysis and Forecast till 2030

The market for brachytherapy was valued at US$ 688.5 million in 2020 and is projected to grow at a compound annual growth rate (CAGR) of 7.50% to reach US$ 1415.8 million by 2030.

A type of radiotherapy called brachytherapy involves placing a bundled radiation source inside or close to the area that has to be treated. Brachytherapy devices are mostly used to treat malignancies in several additional body areas as well as skin, breast, prostate, and cervical cancer. A fixed radiation source is positioned inside or adjacent to the area that needs treatment in brachytherapy, a form of radiotherapy. Brachytherapy is commonly used as an effective treatment for cancers of the skin, esophagus, prostate, cervix, and breast, but it can also be used to treat malignancies in many other body parts. Therapy outcomes have demonstrated that the disease-fixing rates of brachytherapy are either equivalent to a surgical operation or external beam radiation therapy (EBRT) or are enhanced when combined with these techniques. Brachytherapy can be used as a stand-alone treatment or in combination with other therapies such as chemotherapy, EBRT, and medical procedures. Unlike open-source radiation, which involves introducing a useful radionuclide (radioisotope) into the body to artificially confine to the tissue that has to be destroyed, brachytherapy does not do this. It also differs from External Beam Radiation Therapy (EBRT), which targets the tumor externally using high-energy x-rays or sporadic gamma beams from a radioisotope such as cobalt-60. Instead, brachytherapy entails precisely placing short-range radiation sources—such as radioisotopes like iodine-125 or cesium-131—directly at the location of the hazardous tumor. These are protected by a protective wire or casing that prevents the radioisotope charge from migrating or dissolving in bodily fluids while allowing the ionizing radiation to vanish to treat and kill surrounding tissue. The casing may be removed later or, in the case of some radioisotopes, allowed to remain in situ.